VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 510 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2014. The put-call ratio across all filers is 1.37 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $12,000 | +50.0% | 500 | -28.6% | 0.00% | +50.0% |
Q1 2017 | $8,000 | -20.0% | 700 | 0.0% | 0.00% | -33.3% |
Q4 2016 | $10,000 | -41.2% | 700 | 0.0% | 0.00% | -40.0% |
Q3 2016 | $17,000 | +6.2% | 700 | -9.7% | 0.01% | 0.0% |
Q2 2016 | $16,000 | -20.0% | 775 | 0.0% | 0.01% | -37.5% |
Q1 2016 | $20,000 | -33.3% | 775 | +158.3% | 0.01% | -27.3% |
Q4 2015 | $30,000 | +66.7% | 300 | +200.0% | 0.01% | +57.1% |
Q3 2015 | $18,000 | -18.2% | 100 | 0.0% | 0.01% | -12.5% |
Q2 2015 | $22,000 | -45.0% | 100 | -50.0% | 0.01% | -42.9% |
Q1 2015 | $40,000 | +185.7% | 200 | +100.0% | 0.01% | +180.0% |
Q4 2014 | $14,000 | +7.7% | 100 | 0.0% | 0.01% | 0.0% |
Q3 2014 | $13,000 | – | 100 | – | 0.01% | – |
Q2 2014 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
Q1 2014 | $13,000 | +8.3% | 100 | 0.0% | 0.01% | 0.0% |
Q4 2013 | $12,000 | +20.0% | 100 | 0.0% | 0.01% | +25.0% |
Q3 2013 | $10,000 | +11.1% | 100 | 0.0% | 0.00% | 0.0% |
Q2 2013 | $9,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |